CD30

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

TNFRSF8
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8, TNF receptor superfamily member 8
External IDsOMIM: 153243 MGI: 99908 HomoloGene: 949 GeneCards: TNFRSF8
Gene location (Human)
Chr.Chromosome 1 (human)[1]
Band1p36.22Start12,063,303 bp[1]
End12,144,207 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

943

21941

Ensembl

ENSG00000120949

ENSMUSG00000028602

UniProt

P28908

Q60846

RefSeq (mRNA)

NM_001243
NM_001281430
NM_152942

NM_009401

RefSeq (protein)

NP_001234
NP_001268359

NP_033427

Location (UCSC)Chr 1: 12.06 – 12.14 MbChr 4: 145.27 – 145.32 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[5]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.[6] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.[7]

Cancer treatment

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

  1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
  2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
  3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen[8]
  4. Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy[9]

Brentuximab vedotin is also currently being studied in and recommended for treating:

  1. Various types of CD30-positive B cell lymphomas[10]
  2. Various types of CD30-positive T cell lymphomas[11]
  3. CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type[12]


Interactions

CD30 has been shown to interact with TRAF5,[13] and TRAF2.[13]

References
  1. GRCh38: Ensembl release 89: ENSG00000120949 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000028602 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8".
  6. Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese). 34 (11): 711–5. PMID 16536313.
  7. Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology. 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.
  8. Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research. 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.
  9. "FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma". FDA.gov. Retrieved March 2, 2018.
  10. Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F (January 2017). "Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review". Critical Reviews in Oncology/Hematology. 109: 42–50. doi:10.1016/j.critrevonc.2016.11.009. PMC 5218629. PMID 28010897.
  11. Scott LJ (March 2017). "Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma". Drugs. 77 (4): 435–445. doi:10.1007/s40265-017-0705-5. PMC 7102329. PMID 28190142.
  12. Hu B, Oki Y (2018). "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma". Frontiers in Oncology. 8: 139. doi:10.3389/fonc.2018.00139. PMC 5937056. PMID 29761078.
  13. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042–5. doi:10.1074/jbc.272.4.2042. PMID 8999898.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.